{"id":3751,"date":"2025-03-31T18:11:49","date_gmt":"2025-03-31T18:11:49","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/bortezomib-txt\/"},"modified":"2025-03-31T18:11:49","modified_gmt":"2025-03-31T18:11:49","slug":"bortezomib-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/bortezomib-txt\/","title":{"rendered":"Bortezomib.txt"},"content":{"rendered":"

Bortezomib<\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of multiple myeloma for people who have already tried at least 2 prior therapies and have disease progression

DOSE IN NORMAL RENAL FUNCTION <\/H3>1.3 mg\/m2 twice weekly for 2 weeks (days 1, 4, 8 and 11) followed by a 10-day rest period

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :384.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :82.9<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Small amount<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :>500 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :5\u201315\/unknown

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function 10\u201330 Dose as in normal renal function. Monitor carefully.
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : A reduced dose may be required. Monitor carefully

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>3.5 mL sodium chloride 0.9%

    Route <\/H4>IV bolus

    Rate of Administration <\/H4>3 to 5 seconds

    Comments<\/H4>Administer within 8 hours of reconstitution

    OTHER INFORMATION <\/H4>\n
  • Consecutive doses should be at least 72 hours apart\n
  • Normal doses have been used in patients with a GFR of 10\u201330 mL\/min but there is an increased risk of adverse effects. (Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and\/or refractory multiple myeloma. Cancer. 2005; 103(6): 1195\u20131200)\n
  • Some trials have used doses of 1 mg\/m 2 in patients with a GFR of 10\u201330 mL\/min, with similar efficacy and incidence of side effects\n
  • Both hypo- and hyperkalaemia have been reported with bortezomib as has hypophosphataemia and hypomagnesaemia\n
  • There have been incidences of renal impairment, renal colic, proteinuria, dysuria, urinary frequency, urinary hesitation and haematuria\n
  • Anecdotally, has been used at normal doses in a few haemodialysis patients; in some of the patients platelet infusions have been required\n
  • In patients with peripheral neuropathy then bortezomib has a high probability of exacerbating it.
    \n","protected":false},"excerpt":{"rendered":"

    Bortezomib CLINICAL USE Treatment of multiple myeloma for people who<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3751","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3751"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3751\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}